Myfortic (Mycophenolic Acid)

Mycophenolic Acid blocks the enzyme inosine monophosphate dehydrogenase, which is essential for making guanosine nucleotides. This limits the proliferation of T‑ and B‑lymphocytes, the immune cells responsible for attacking transplanted tissue, thereby reducing the risk of rejection.

The dosage of Myfortic is individualized by the prescribing physician based on the patient’s transplant type, renal function, and other clinical factors. Patients should follow the exact dosing instructions provided by their healthcare professional.

The safety of Myfortic in pregnancy and lactation has not been established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their transplant team before using this medication.

To request Myfortic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myfortic (mycophenolic acid) is an antimetabolite that specifically inhibits lymphocyte proliferation, whereas calcineurin inhibitors such as tacrolimus act on T‑cell activation pathways. Myfortic is often used in combination with other agents to achieve synergistic immunosuppression while offering a different side‑effect profile.

Myfortic should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the tablets out of reach of children and do not use them after the expiration date.

Myfortic is taken orally as a delayed‑release tablet, usually once or twice daily as directed by the transplant physician. The tablets should be swallowed whole with water and not crushed, chewed, or split.

Serious risks include severe infections due to immune suppression, leukopenia (low white blood cell count), and hepatotoxicity (liver injury). Patients should be monitored regularly for signs of infection, blood count changes, and liver function abnormalities.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolic acid or any of the tablet’s excipients. It should also be avoided in individuals with uncontrolled severe infections or active malignancy unless specifically directed by a specialist.